Catalyst Biosciences Inc. (CBIO)

CBIO stock forecast: buy or sell

CBIO stock outlook

  • Catalyst Biosciences closed today at $5.59 after sliding a -1.24%.
  • Looking at the chart, price is drawing an scaled downtrend since last February with lower tops and lower bottoms. this downtrend marked a -37.47% loss.
No ad for you

Important note:
The opinions written in this article are personal and not recommendations for you to buy or sell stocks. The author of this document does not have any knowledge of the individual conditions of the reader, his or her finances or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Viewpoints are published for education purposes only

CBIO stock chart overview

Should I buy Catalyst Biosciences stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is CBIO stock a buy?

Currently, Catalyst Biosciences stock doesn't match any of these trading strategies, so our recommendation is not to buy now. This doesn't mean we expect a selloff for CBIO in coming sessions, or that it may not climb higher. Simply, it doesn't match our recommended trading systems

No ad for you

Should I sell Catalyst Biosciences stock?

"To sell or not to sell", if you are holding Catalyst Biosciences shares?. Trading strategies allow us to avoid impetuous decisions based on our emotions or the buzz surrounding the market. We like very simple strategies to guide us on when is the best moment to sell our shares. Be aware that these strategies are not intended for shorting CBIO stock

As a rule of thumb, you must never hold an open trade that results in greater losses than those expected at the time of the buy. The moment to sell your stock always has to be determined by the stop-loss (automatic or manual)

Is it time to sell Catalyst Biosciences stock?

In the current situation of Catalyst Biosciences there is not any eligible sell setup, so Catalyst Biosciences stock holders with operations in profit can keep their positions

No ad for you

Analysts' recommendations to buy or sell Catalyst Biosciences stock

Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal

In the last month, just one analyst rating was published for Catalyst Biosciences

No ad for you

Catalyst Biosciences ratings

Brokerage firmRating
Jun 17th, 2020
Raymond James Buy

Technical analysis

Catalyst Biosciences accumulates a selloff of -37.47% since its latest top last February at $8.94. Like in all downtrends, the stock oscillates drawing lower tops and bottoms. In this case, we have seen 2 consecutive lower tops

SMAs overview

A favorite tool of many technical analysts are the moving averages, that easily show trend momentum. A moving average is the average price of a stock over a set period of time. Moving averages are usually calculated on different periods depending on the trading timeframe 21, 50, 100 and 200 days are the most usual moving averages. Learn more about Moving Averages from sources like Wikipedia and Investopedia

Supports and resistances

Investors use support and resistance levels as a way to find price points in the stock price action that may behave as obstacles, preventing the price of a stock to move in certain direction. Supports are levels where the price tends to stop as it falls. Price is more likely to "rebound" this level rather than break through it. However, if the price breaks down this level, it will probably continue declining until approaching another support level. In contrast, a resistance level is where the price may find a curb as it rises. Again, the price is more likely to "rebound" at this level, and if it finally ruptures this level, the price will rally more easily until it finds the next resistance

The current resistance levels are:

  • R1: $5.60 (0.18% above)
  • R2: $5.71 (2.15% above)
  • R3: $5.79 (3.58% above)
  • The current supports are:

  • S1: $5.25 (-6.08% below)
  • S2: $5.12 (-8.41% below)
  • S3: $5.05 (-9.66% below)
  • Bollinger bands

    This is an indicator that was introduced in the 1980s by John Bollinger. It is made up of 3 lines that are outlined superimposed on the price evolution chart:

    • The central band is a moving average, usually a simple moving average calculated with 20 periods
    • The upper band is calculated by adding to the value of the simple moving average 2 times the standard deviation of the moving average
    • The lower band is calculated by subtracting from the simple moving average 2 times the standard deviation of the moving average

    Relative strength index

    The relative strength index (RSI) is a technical indicator used in the analysis of financial markets. Its objective is to map the current and previous strength or weakness of a stock or market based on the closing prices of a recent trading period. Oscillator indicators, such as relative strength, are intended to indicate values in the range of 0-100. The relative strength indicator is one of the best known and most widely used indicators, and it was invented by J. Welles Wilder in the late 1970s

    The RSI dropped below the overbought level of 70 in late May after just crossing to the overbough zone for 1 day (weak signal). The RSI value today was 34.49. Catalyst Biosciences stock sank a 28.79% since that level was lost

    No ad for you

    Earnings and financials

    CBIO had the quarterly investors call and released the Q1 report in mid-May. CBIO posted first-quarter earnings of $-0.28 per share on sales of $16.4 million. The analysts estimate was $-0.37 per share on revenue of $16.4 million.

    Compared to the same quarter one year ago, EPS was $-1.26, so current EPS is a improvement of 77.78%. Looking at turnover, figures skyrocketed a 5046.54% compared to $3,180,000 same quarter last year.

    CBIO is hosting the quarterly earnings call on Thursday next week. Forecasted earnings of %s per-share for this quarter is $-0.87. Earnings reporting day has an additional risk for traders as the data disclosed can soar and sink the stock price with very low volume and not respecting your buy or stop-loss orders. Check company's website to confirm time and details about the earnings call and the earnings report.

    No ad for you